Go Pro
OTCMKTS:MKKGY

Merck KGaA Q3 2025 Earnings Report

Merck KGaA logo
$31.66 +0.80 (+2.59%)
As of 03:53 PM Eastern

Merck KGaA EPS Results

Actual EPS
$0.81
Consensus EPS
$0.54
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Merck KGaA Revenue Results

Actual Revenue
$6.17 billion
Expected Revenue
$6.08 billion
Beat/Miss
Beat by +$86.79 million
YoY Revenue Growth
N/A

Merck KGaA Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Merck KGaA's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Merck KGaA Earnings Headlines

First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
See More Merck KGaA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck KGaA and other key companies, straight to your email.

About Merck KGaA

Merck KGaA (OTCMKTS:MKKGY) is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. Merck KGaA operates independently from the U.S.-based Merck & Co., Inc., which uses the name MSD in markets outside the United States and Canada.

The company operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing equipment and services used by academic institutions, pharmaceutical manufacturers and other industrial customers. Healthcare activities include prescription medicines and specialty treatments, with products addressing areas such as oncology, neurology and immunology, as well as fertility and endocrinology.

Merck KGaA’s Electronics business develops materials and solutions used in semiconductor manufacturing and display technologies, including specialty chemicals, photoresists and materials for liquid-crystal and OLED applications. The company serves customers in markets around the world through an international research, manufacturing and commercial network. Belén Garijo serves as chair of the company’s executive board and chief executive officer.

View Merck KGaA Profile